SSY Group Wins First PRC Approval for New Fat-Soluble Vitamin Injection

SSY Group ( (HK:2005) ) has shared an update.

SSY Group has received approval from China’s National Medical Products Administration to produce and register its Fat-soluble Vitamin Injection (Ⅱ) 10ml, classified as a type 3 chemical drug that has passed consistency evaluation. The product, the first of its kind approved for a PRC entity, is designed to meet daily physiological needs for fat-soluble vitamins A, D2, E and K1 in adults and children over 11, marking a notable expansion of the group’s injectable nutrition portfolio and reinforcing its positioning in China’s regulated pharmaceutical market.

The announcement, issued on a voluntary basis, signals ongoing progress in SSY Group’s product development pipeline and provides shareholders and potential investors with an update on its business development. By securing first-mover status for this particular vitamin injection formulation in China, the company may gain a competitive edge in hospital procurement and broader clinical use, supporting future revenue diversification within its core injectable drug segment.

The most recent analyst rating on (HK:2005) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited is a pharmaceutical company listed in Hong Kong, engaged in the development and production of injectable drugs. The group focuses on supplying the Chinese healthcare market with specialized formulations, including chemical drug injections used in hospitals and clinical settings across the mainland.

Average Trading Volume: 8,037,797

Technical Sentiment Signal: Sell

Current Market Cap: HK$7.38B

Learn more about 2005 stock on TipRanks’ Stock Analysis page.